福瑞达20251113

Summary of the Conference Call for Furuida Company Overview - Company: Furuida - Year: 2025 - Industry: Cosmetics, Pharmaceuticals, and Raw Materials Key Points Overall Performance Expectations - Furuida's overall performance in 2025 is expected to be flat, with a slight decline in cosmetics business, stable growth in raw materials, and pressure in the pharmaceutical sector [2][29][30] Brand Performance - Yilian Brand: Despite a decline during the Double Eleven sales event, the annual growth expectation remains at 15%-20%, with the cooking series products performing well and improving overall gross margin [2][5] - Doctor Brand: The probiotic series adjustment is nearing completion, with some face masks resuming shipment. Positive growth is anticipated for next year [2][11] - Kemi Brand: Expected to achieve triple-digit growth, with sales projected to reach around 100 million due to the success of the Chuangmo peptide technology and collaboration with Xinhua Net [2][21] Raw Materials Business - Significant growth in the raw materials business in Q3, driven by high demand for food-grade and cosmetic-grade hyaluronic acid, as well as rapid expansion in the overseas market for pharmaceutical-grade hyaluronic acid [2][25][27] Sales Channels - Douyin has become the largest sales channel, accounting for approximately 60% of online sales, while Tmall accounts for about 40% [8][6] - The self-broadcasting and other channels have maintained rapid growth despite the absence of top-tier influencer collaborations [6][8] Product Structure and Innovations - The proportion of spray products in the Yilian brand has risen to over 70% due to successful sales of the spray kit endorsed by Zhang Linghe [9] - The 287 series is positioned to replace the original probiotic series, focusing on specific skin issues and improving product quality [16] Future Plans and Strategies - Plans to advance equity incentives and acquisition strategies in 2026, with preparations already underway [12][34] - The company is exploring new directions in the pharmaceutical sector, including online pharmacies and health food products, although these require time and investment for scaling [28] Market Outlook - The company remains optimistic about 2026, expecting positive effects from current adjustments and a favorable market environment [29][33] - The pharmaceutical business is under pressure, but the company is actively seeking new growth avenues [28] Financial Performance - The company aims to improve profitability through enhanced gross margins and various measures despite a flat overall performance in 2025 [30] Regulatory and Certification Updates - Anticipation of receiving three types of certifications for pharmaceutical-grade hyaluronic acid by late 2026 or early 2027, which could significantly boost sales [23][24] Competitive Landscape - The competition between Tmall and Douyin is seen as beneficial, providing more promotional opportunities for the company [19] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Furuida's current performance, brand dynamics, market strategies, and future outlook.